New Targeted Therapies and Small-Cell Lung Cancer

Rossi, Antonio; Maione, Paolo; Palazzolo, Giovanni; Sacco, Paola Claudia; Ferrara, Marianna; Falanga, Marzia; Gridelli, Cesare

doi:10.3816/clc.2008.n.042

Cited by 39 publications

(25 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, it remains to be determined whether this approach has any survival benefit. In addition, there are ongoing trials evaluating targeted agents such as gefitinib, sorafenib, bevacizumab, and thalidomide in SCLC (35). These findings may stimulate the search for, and design of, clinical trials to test targeted therapies for the treatment of SCCUC.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix

2011

View full text Add to dashboard Cite

Abstract. Small cell carcinoma of the uterine cervix (SCCUC) is rare and its biologic behavior is aggressive. To analyze prognostic factors and determine optimal therapy in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA SCCUC, we retrospectively reviewed 96 patients (14 patients treated in our center and 82 patients identified by a search on PubMed) treated with radical surgery (SU), surgery plus adjuvant chemotherapy (SU+Chemo), or surgery plus adjuvant chemotherapy and radiotherapy (SU+Chemo+RT) between 1990 and 2010. Of the 96 patients, 11 patients were treated with SU, 33 with SU+Chemo, and 52 with SU+Chemo+RT. The 5-year survival rate for the 96 patients was 45%. A total of 6% (2/32) of patients had local recurrence, 75% (24/32) had distant metastases, and 19% (6/32) had both. The 5-year survival rate in stage IB1 and IB2-IIA disease was 58 and 34%, respectively (P=0.049). For patients with and without lymph node metastases (LNM), survival was 33 and 60%, respectively (P=0.045). Patients with inner 1/3 stromal invasion had a better survival than those with deep stromal invasion (DSI) (100 vs. 34%, P=0.003). Survival was not significantly different in patients treated with the above three modalities, albeit treatment selection was related to LNM (P=0.000) and DSI (P=0.027). Thus, FIGO stage, LNM and DSI are significant predictors of survival. Adjuvant therapy after SU has not improved survival compared with surgery alone. Thus, newer multimodality therapy should be evaluated.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix

2011

View full text Add to dashboard Cite

show abstract

“…Development in translational research and increasing understanding of the molecular basis of cancer has facilitated to identify a number of molecular targets for cancer treatment in various preclinical studies. Theoretically, targeted drugs should bring out less toxicity than conventional chemotherapy drugs, but no such targeted agents have been approved for use in the treatment of SCLC patients and negative results are more commonly reported than positive ones (Rossi et al, 2008). Therefore, to develop highly efficient targeted agents is urgently needed.…”

Section: Discussionmentioning

confidence: 99%

“…However, negative results are currently more commonly reported than positive ones, there are still no targeted drugs applied in the treatment of SCLC (Rossi et al, 2008 andSgambato et al, 2013). So it is urgent to obtain better understanding of the molecular mechanism of SCLC and look for better targeted therapies.…”

Section: Introductionmentioning

confidence: 99%

Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer

Liang

Yang

Jiang

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…To date, there are no established histological or molecular features of prognostic utility [33]. Treatment options remain limited beyond first line platinum and etoposide chemotherapy, with no role for targeted agents [34].…”

Section: Small Cell Lung Cancermentioning

confidence: 99%

Predictive and prognostic value of circulating tumor cell detection in lung cancer: A clinician's perspective

Tognela¹,

Spring²,

Becker³

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

New Targeted Therapies and Small-Cell Lung Cancer

Cited by 39 publications

References 45 publications

Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix

Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix

Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer

Predictive and prognostic value of circulating tumor cell detection in lung cancer: A clinician's perspective

Contact Info

Product

Resources

About